Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung

Walter Z. Wang1,2, Konstantin Shilo3, Joseph M. Amann1,2, Alyssa Shulman1,2, Mohammad Hojjat-Farsangi4, Håkan Mellstedt4, Johan Schultz5, Carlo M. Croce2,6 and David P. Carbone1,2

Abstract
Small cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in multiple tumor types due to microRNA coregulation. We hypothesize that ROR1-targeted therapy is effective in small cell lung cancer and synergizes with therapeutic BCL2 inhibition. Tissue microarrays (TMAs) and formalin-fixed paraffin-embedded (FFPE) SCLC patient samples were utilized to determine the prevalence of ROR1 and BCL2 expression in SCLC. Eight SCLC-derived cell lines were used to determine the antitumor activity of a small molecule ROR1 inhibitor (KAN0441571C) alone and in combination with the BCL2 inhibitor venetoclax. The Chou-Talalay method was utilized to determine synergy with the drug combination. ROR1 and BCL2 protein expression was identified in 93% (52/56) and 86% (48/56) of SCLC patient samples, respectively. Similarly, ROR1 and BCL2 were shown by qRT-PCR to have elevated expression in 79% (22/28) and 100% (28/28) of SCLC patient samples, respectively. KAN0441571C displayed efficacy in 8 SCLC cell lines, with an IC50 of 500 nM or less. Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.

Introduction
Small cell lung cancer (SCLC) has a 5-year survival rate of only 6 percent, with no approved targeted therapies, underscoring the need for novel therapeutics1. While little progress was made over many decades in the treatment of SCLC, in 2019 first-line chemotherapy/immunotherapy for extensive-stage disease was approved2. The addition of atezolizumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), to standard chemotherapy increased median overall survival by 2 months to a total of 12.3 months, though objective response rate and median duration of response remained similar between both arms2. While this is promising, there is still a great necessity to develop novel and more efficacious treatments for SCLC.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a receptor tyrosine kinase-like protein that has been implicated to play a role in many different types of cancer3–8. ROR1 has oncofetal expression, as it is an embryonic protein that is not normally expressed in differentiated cells, but can be re-expressed in cancer cells9. Thus, ROR1-targeted therapy could be tumor specific, and a recent study has demonstrated that ROR1 expression is correlated with worsened patient outcomes in lung adenocarcinomas5. ROR1 inhibition has been shown to lead to cell death in pancreatic, leukemia, and lung cancer cells, suggesting that it is a viable therapeutic target4,7,10–13.
Therapies targeting ROR1 have also seen early efficacy for treating hematological malignancies\(^{10,14}\). Interestingly, it has been shown in chronic lymphocytic leukemia (CLL) that the loss of microRNAs (miRNAs) miR-15a/16-1 is associated with the aberrant expression of ROR1\(^{15}\). miRNAs are small non-coding RNA molecules that silence the expression of their target mRNAs, acting as negative regulators. Strikingly, the same miRNAs that appear to regulate ROR1 expression in CLL are also responsible for the regulation of the expression of the anti-apoptotic factor BCL2\(^6\). Recent studies in CLL have shown that an inhibitory antibody targeting ROR1, cirtuzumab, in combination with the BCL2 inhibitor venetoclax demonstrated synergy, indicating that the combined therapy has a greater clinical impact than either therapy alone\(^8\). Identification of such mechanism-based drug combinations are commonly used in cancer treatment, with the aims of increasing the therapeutic effect, reducing individual drug dose and subsequent toxicity as well as delaying the onset of drug resistance\(^{16,17}\). Drug synergy is critical in the determination of drug combinations, as it is necessary to investigate whether the drugs are working in concert or antagonistically. BCL2 is known to be expressed in SCLC, but targeted monotherapy has not shown significant clinical impact\(^{18}\). Examining SCLC samples for co-expression of ROR1 would suggest combination therapies targeting both BCL2 and ROR1 to improve therapeutic effects while reducing treatment-related side effects.

Here, we investigated the prevalence of ROR1 expression in SCLC patient samples and determined the effectiveness of ROR1 inhibition alone and its potential synergy with BCL2 inhibition in SCLC cell lines.

**Methods**

**Cell cultures, drugs, and growth assay**

SCLC cell lines, H69, H82, H146, H187, H209, H211, H1417, and H1963 were grown in Roswell Park Memorial Institute (RPMI) media with 10% fetal bovine serum (Gibco, Waltham, MA; CN: 11865101). Cell lines were purchased from ATCC (Manassas, VA), authenticated and tested for mycoplasma contamination. Venetoclax was purchased from Selleckchem, Houston, TX (CN: S8048) and KAN0441571C was a gift from Kancera, Solna, Sweden. Cells were plated 12 h prior to start of drug treatment, which lasted for 72 h for all cytotoxicity experiments. Cell viability was estimated by alamarBlue Cell Viability Reagent (ThermoFisher, Waltham, MA; CN: DAL1100) per manufacturer’s instructions.

shRNA knockdown experiments were performed using the pLKO.1-puro vector. To knockdown ROR1 expression, we used ROR1 Mission shRNAs (Sigma, SHCLNG-TRCN0000002024 and SHCLNG-TRCN0000002025) or non-targeting control (Sigma, SHCO16). Lentiviral particles were produced by transfecting 293FT packaging cells with packaging-psPAX2, envelope-pMD2.G and shRNA plasmid as previously described\(^{19}\).

**Development of ROR1 tyrosine kinase inhibitor KAN0441571C**

The development of the first small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) was recently described\(^{10}\), and continued development has resulted in a more potent second generation ROR1 inhibitor KAN0441571C\(^{20}\).

In brief, a high-throughput screen targeting the tyrosine kinase domain of ROR1 was performed and in the following hit-to-lead and lead optimization stages more than 2000 compounds have been synthesized. The basic scaffold of both KAN0439834 and KAN0441571C was identified in the HTS and was shown to be ATP-competitive, thus the binding site is most probably in the ATP binding pocket of the tyrosine kinase domain. Since the discovery of KAN0439834, approximately 950 additional compounds have been synthesized and tested for cytotoxic effect against primary CLL cells from patients as well as peripheral blood mononuclear cells (PBMC) from healthy donors, leading to the discovery of KAN0441571C. The compound shows a high degree of “drug likeness” as it contains no apparent toxicophores and adheres to criteria typical for an orally active drug (Supplementary Table 1)\(^{20}\). The molecular weight is 555 g/mol, the calculated cLogD7.4 is 1.7 and the calculated polar surface area is 73 Å\(^2\). Compared to the first generation ROR1 inhibitor (KAN0439834), the most important improvements of the second generation compound (KAN0441571C) are a higher cytotoxic potency against various cancer cells in vitro and a substantially longer serum half-life (T1/2) in the mouse (11 h compared to 2.1 h).

**Immunohistochemistry**

Tissue microarray (TMA) based samples from surgically resected small cell lung carcinomas (SCLC) were utilized for ROR1 and BCL2 protein expression in human samples. The staining was interpreted as negative (including weak) versus positive (including moderate and strong). IHC staining was performed on paraffin-embedded tissue as previously described\(^{21}\). In brief, embedded tissue was cut a 4-µm utilizing positively charged slides, placed in a 60°C oven for 1 h, cooled, deparaffinized and rehydrated utilizing xylens and graded ethanol solutions to water. All slides were quenched for 7 min in a 3% hydrogen peroxide aqueous solution to block for endogenous peroxidase. For ROR1 antibody (Rabbit polyclonal, Abcam, ab135669) staining, antigen retrieval was performed by heat-induced epitope retrieval (HIER) in which the slides were placed in a 1× solution of Target Retrieval Solution (Dako, S2367) for 25 min at ≥96°C using a vegetable
steamer (Black & Decker), then cooled for 15 min in solution. Slides were then stained with Dako Link 48 Autostainer Immunostaining System (Agilent Technologies) at room temperature for 60 min, with antibody at a 1:400 dilution. EnVision Flex Mini-Kit HRP (Dako, K8023) was applied for 30 min, then staining was visualized with EnVision Flex DAB-substrate chromagen (Dako, included in EnVision Flex Mini-Kit) applied for 10 min. Slides were counterstained in hematoxylin (Dako/Agilent #SK203), dehydrated through graded ethanol solutions, cleared with xylene, and coverslipped. For BCL2 antibody (Mouse monoclonal, Dako, clone 124), antigen retrieval was performed on-line using Leica antibody (Mouse monoclonal, Dako, clone 124), antigen solutions, cleared with xylene, and coverslipped. For BCL2 10 min. Slides were counterstained in hematoxylin (Dako/Agilent #SK203), dehydrated through graded ethanol solutions, cleared with xylene, and coverslipped. For BCL2

Quantitative RT-PCR

Total RNA was isolated using the miRNeasy Kit (Qia-gen, Hilden, Germany; CN: 217084) or miRNeasy FFPE Kit (Qiagen; CN: 217504) according to the manufacturer’s instructions. Synthesis of cDNA from total RNA (100 ng) was performed using a High-Capacity cDNA Reverse Transcription Kit following manufacturer’s instructions (Applied Biosystems, Foster City, CA; CN: 4368814). Reverse transcription thermo cycling parameters were 25 °C for 10 min, 37 °C for 120 min and 85 °C for 5 min for mRNA, or 16 °C for 30 min, 42 °C for 30 min and 85 °C for 5 min for miRNA. Reactions were performed on a MyCycler (Bio-Rad, CA, USA). Quantitative real-time PCR was performed in triplicate using the ViiA7 system in 10 μl reaction volumes containing 5 μl of PCR master mix (Taqman 2x Universal PCR master mix, Applied Biosystems, CN: 4324018) each primer-probe 0.5 μl, 3.5 μl of nuclease-free water, and 1 μl of cDNA (total 10 μl) in optical 384-well plates (Applied Biosystems). qPCR cycling conditions were: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. Triplicate qPCR reactions were performed for each cDNA sample for all experiments. The threshold fluorescence level was set automatically for each plate using QuantStudio Real-Time PCR Software (Applied Biosystems). All probes (ROR1: Hs00938677_m1, CN: 4331182; BCL2: Hs00608023_m1, CN: 4331182; GAPDH: Hs02766624_g1, CN: 4331182) utilized were TaqMan Gene Expression assays purchased from ThermoFisher Scientific. Human Lung Total RNA used as a control was purchased from ThermoFisher Scientific. Results were normalized using GAPDH expression levels. Correlation analyses were conducted using Spearman’s rank correlation coefficient in the R programming language.

Statistical analysis

Statistical analyses were performed using Graphpad Prism version 8. Differences were considered significant when the p values were less than 0.05.

Synergy analysis

We obtained dose curves for venetoclax and KAN0441571C as single agents and in constant ratios of their IC50 values to determine to what degree these agents showed synergy. Combination index (CI) scores were calculated as previously described utilizing CompuSyn software (ComboSyn, Inc), which uses the Chou-Talalay combination index method based on the principles of the median-effect equation. Synergy of two agents was defined as CI < 1, additivity as 1 < CI < 1.5, and antagonism as CI > 1.5. Iso-bolograms were also drawn utilizing CompuSyn to visualize synergy. In brief, the amount of each individual drug needed to achieve an effect of 50, 75, and 90 percent is calculated and used as intercepts to generate an isobole connecting those points. Dose pairs for the combination therapy are then plotted, with points below the isobole are considered synergistic, on the isobole additive, and above the isobole antagonistic.

Western blotting

Western blot analysis was performed following standard procedures. Whole-cell protein lysates were prepared using RIPA buffer with cOmplete™ Mini protease inhibitor (Sigma, CN: 1183617001) and PhosSTOP (Sigma, CN: 4906845001). Protein concentrations were assayed using the Pierce BCA assay (ThermoFisher, CN: 23225), then equal amounts of protein were suspended in SDS loading buffer with DTT, separated on Criterion TGX gels 4–15% SDS-PAGE gels (BioRad, CN: 5671084), and transferred onto PVDF membrane using the Transblot Turbo (BioRad) system. The membranes were then treated with appropriate antibodies according to the methods recommended by their manufacturer and LiCor, then imaged on a LiCor CLx imager. The following antibodies were used in this study: ROR1 (1:1000 dilution, CN: D6T8C), BCL2 (1:1000 dilution, CN: 15071) and β-actin (1:1000 dilution, CN: 3700) from Cell Signaling Technologies. Phospho-ROR1 antibody (1:250 dilution) was a gift from Kancera, and was produced as previously described.

Results

ROR1 and BCL2 are co-expressed in patient samples of SCLC

To investigate SCLC for ROR1 and BCL2 co-expression, we evaluated tissue microarray-based samples from SCLC
patients by immunohistochemistry. SCLC showed frequent diffuse cytoplasmic expression of ROR1 and BCL2 (Fig. 1). Positive expression was defined by scoring IHC staining on a scale of 0–3+, with representative images shown (Supplementary Fig. 1). ROR1 expression was identified in 93% (52/56) of SCLC tumors, while BCL2 expression was identified in 86% (48/56) of SCLC tumors, and 83% (45/56) of SCLC tumors showed expression of both ROR1 and BCL2 in the same tumor cells. It was observed that in positive samples all tumor cells stained for ROR1 and BCL2 expression. This confirms that a majority of SCLC express ROR1 and BCL2, suggesting that a ROR1-targeted therapy could be effective in SCLC patients alone or in combination with BCL2 inhibition (Table 1).

We then extracted RNA from 28 formalin-fixed paraffin-embedded (FFPE) SCLC patient biopsy samples to analyze for ROR1 and BCL2 expression via RT-qPCR to corroborate the results seen via IHC. Of these samples, 82 percent (23/28) were stage 3–4 and 11 percent (3/28) were treated prior to biopsy (Supplementary Table 1).

Results were compared to Human Lung Total RNA as a normal control, and elevated expression of ROR1 and BCL2 was defined as the relative mRNA expression of >2 compared to control, with results being normalized to GAPDH expression levels. We found that 79 percent (22/28) of the samples had elevated ROR1 expression compared to normal, and 100 percent (28/28) of samples had elevated BCL2 expression (Fig. 2A). Of those, 79 percent (22/28) had both elevated ROR1 and BCL2 expression, which correlates well with what was observed in the TMA analysis. To further validate these results, we utilized published SCLC sequencing data from 81 patient samples to determine that 92 percent (78/81) and 100 percent (81/81) of samples expressed ROR1 and BCL2, respectively. Active gene expression was defined as having a zFPKM score of greater than −3 as defined in the previous studies. These data corroborate our observations of ROR1 and BCL2 expression via IHC and RT-qPCR. To investigate the role of miRNA-15/16 in the regulation of ROR1 and BCL2 expression in SCLC, we performed RT-qPCR to determine the expression of miR-15a, miR-15b, and miR-16 in these SCLC FFPE samples. Their expression levels are plotted against each other, as well as BCL2 and ROR1 relative expression (Supplementary Fig. 2). We found that there was a positive correlation between the expression of the miRNAs with each other, as well as between BCL2 and ROR1 expression. Additionally, we determined that there is a negative correlation between the expression of the miRNAs and the expression level of BCL2 and ROR1, suggesting that the expression of these miRNAs may act as a negative regulator of ROR1 and BCL2 expression in SCLC as previously described in CLL.
Single agent ROR1 inhibition, but not BCL2 inhibition alone, is effective in in vitro models of SCLC

In order to investigate the efficacy of ROR1 inhibition in vitro, we characterized 8 SCLC cell lines (H69, H82, H146, H187, H209, H211, H1417, and H1963) for ROR1 and BCL2 expression (Fig. 2B), normalizing gene expression to GAPDH. Of these, all 8 had elevated ROR1 and BCL2 expression compared to HBEC-3KT cells, which are immortalized human bronchial epithelial cells. H146 cells had the lowest expression level of ROR1, with a relative mRNA expression of a factor of approximately 2 compared to HBEC-3KT control. As these results are consistent with the data shown in human samples, we used these SCLC cell lines to test the efficacy of ROR1 and BCL2 inhibition in vitro. For each cell line we generated dose-response curves of a novel small molecule ROR1 inhibitor, KAN0441571C (Fig. 3A and Supplementary Fig. 3), as well as a BCL2 inhibitor, venetoclax (ABT-199) (Fig. 3B and Supplementary Fig. 4), to determine the relative cell viability and the IC\textsubscript{50} of each drug. BCL2 inhibition via venetoclax as a single agent showed limited efficacy in the SCLC cell lines, with an IC\textsubscript{50} of 16.7 μM on average. In contrast, KAN0441571C as a single agent showed efficacy at lower levels, with an IC\textsubscript{50} of 299 nM on average (Supplementary Table 2). These results suggest that ROR1 may be a viable target for SCLC therapy, even as a monotherapy.

KAN0441571C and venetoclax synergize as a combination therapy against SCLC cell lines

We next wanted to determine whether ROR1-targeted therapy and BCL2 inhibition would demonstrate synergy. Here, we determined synergism utilizing calculated combination index (CI) values via the Chou-Talalay method derived from the mass-action law, as well as isoboles to quantitatively determine synergy between KAN0441571C and venetoclax. A constant ratio of 1:50 KAN0441571C to venetoclax was chosen for these experiments from the average IC\textsubscript{50} value of each individual drug. Fa was defined as percent cell death with 1 indicating complete cell death, Dose A as KAN0441571C, Dose B as venetoclax, and Combo as the combined treatment of KAN0441571C and venetoclax. We determined synergy in all eight tested SCLC cell lines, though some had additivity at lower Fa value (Fig. 4A and Supplementary Fig. 5). For H69 cells, due to the initial experimental points being clustered in high Fa values, an additional experiment was performed utilizing a 1:1 ratio of KAN0441571C to venetoclax, which resulted in additional points that fit well along the initially calculated CI.
values. In isobole analysis, nearly all cell lines demonstrated synergy at $F_a$ values of 0.5, 0.75, and 0.9 (Fig. 4B and Supplementary Fig. 6). These data indicate that ROR1-targeted therapy synergizes with BCL2 inhibition across a range of SCLC cell lines and would demonstrate synergy and suggest potential efficacy in treating SCLC patients.

**Synergy between venetoclax and KAN0441571C is not due to off-target effects of KAN0441571C**

Since KAN0441571C is a novel candidate drug, we wanted to be certain that the drug was inhibiting the intended target, ROR1. First, we demonstrated that treating H69 cells with KAN0441571C decreased phospho-ROR1 levels in a dose-dependent manner upon Western blot analysis (Supplementary Fig. 7). Furthermore, we show that levels of phospho-ERK, a downstream effector of ROR1 signaling, also decreased in a dose-dependent manner 30 min after KAN0441571C application in both H69 and H82 cell lines, and that levels of both total and active (non-phosphorylated) $\beta$-catenin levels decrease over a time course of 3 days after 1 $\mu$M KAN0441571C treatment (Supplementary Fig. 8). These findings reflect previously published data that demonstrated ROR1 inhibition decreased canonical Wnt-signaling through inactivation of $\beta$-catenin, dephosphorylated Src, and inhibited the PI3K/AKT/mTOR pathway$^{10,12,20}$. We then performed shRNA-mediated knockdown of ROR1 in H69 and H82 cell lines and noted a significant decrease in relative cell survival after 72 h of growth compared to untreated parental controls and non-targeting control (NTC). With the addition of 25 $\mu$M venetoclax, the calculated cell viability IC$_{50}$ of venetoclax for H69 cells, we noted a significant decrease in relative survival compared to ROR1 shRNA alone (Supplementary Fig. 9). These data suggest that the effects we are observing with KAN0441571C are on-target.

As an additional test for specificity, we performed KINOMEsCan™ profiling (DiscoverX, San Diego, CA, USA) to identify off-target effector kinases of KAN0441571C, followed by determination of potencies in a kinase activity assay (Flashplate-based radiometric $^{33}$P assay; ProQinase, Freiburg, Germany). According to these assays, the kinases that have the greatest potential to be off-targets for KAN0441571C are CDK4, CDK6, and CDK9, which could be responsible for the effects and synergy demonstrated by KAN0441571C and venetoclax (Supplementary Table 3). To investigate whether the inhibition of these potential off-target kinases CDK4 and CDK9 is responsible for the synergy between
KAN0441571C and venetoclax, we utilized the CDK4/6 inhibitor abemaciclib and the CDK9 inhibitor SNS-032 in combination with venetoclax in H69 and H82 cells (Supplementary Fig. 10). Cells were treated with a ratio of 1:5 of abemaciclib or SNS-032 to venetoclax based on preliminary IC50 values. What we observed in these two cell lines was mostly additive. With SNS-032, slight synergy with venetoclax was observed at high Fa in H69 cells, but not at the levels seen with KAN0441571C. In H82 cells, SNS-032 demonstrated only additivity with venetoclax. Abemaciclib showed no synergy with venetoclax in either cell line, as we obtained CIs between additivity and antagonism in both. These results indicate that the synergy found between KAN0441571C and venetoclax is a result of on-target ROR1 specific inhibition, rather than modulation or inhibition of another kinase.

**Discussion**

Our study shows that ROR1 is commonly expressed in SCLC, and that it is a potential therapeutic target that would have broad therapeutic value to SCLC patients in a targeted, tumor-specific manner. We demonstrate the efficacy of a novel, small molecule ROR1 inhibitor, KAN0441571C, in SCLC in vitro. Novel small molecule targeted therapies are urgently needed in SCLC, as none are currently available to supplement the current standard-of-care of chemotherapy with or without monoclonal antibodies against programmed death-ligand 1 (PD-L1). This standard therapy has significant systemic toxicities, and almost all patients relapse eventually, needing other therapy options. ROR1-targeted therapy is expected to be more cancer-specific than chemotherapy, with fewer side effects due to its oncofetal expression. Cirmtuzumab, an inhibitory monoclonal antibody targeting ROR1, has already undergone a Phase I clinical trial in CLL patients with the conclusion that it is safe and well tolerated. ROR1 chimeric antigen receptor-specific autologous T-lymphocytes (CAR-T) therapy is undergoing clinical trials in triple-negative breast cancers (TNBC) and non-small cell lung cancers (NSCLC). With ROR1-targeted therapy already showing promising signs of activity in various cancer types, KAN0441571C brings the added benefits of being a small molecule inhibitor that directly inhibits the tyrosine kinase domain of a selectively overexpressed kinase, ROR1. This makes it more likely that KAN0441571C will have increased bioavailability and better penetration into solid tumors, as
well as more easily cross the blood-brain barrier compared to larger therapeutic molecules28.

Additionally, our study demonstrated that most tumors co-express higher than normal amounts of BCL2 and ROR1 compared to normal controls, which may be at least in part due to lower levels of miR-15/16. The fact that these two proteins are both overexpressed in SCLC led us to examine the combination of a targeted ROR1 inhibitor and a BCL2 inhibitor. We noted a marked synergy between ROR1-targeted therapy and BCL2 inhibition utilizing the FDA-approved inhibitor venetoclax, a drug that has demonstrated efficacy in other malignancies such as CLL and acute myeloid leukemia (AML) as well as preliminary efficacy in SCLC models with high levels of BCL2 expression29–32. While there is some concern regarding dose-limiting toxicities such as tumor lysis syndrome in hematologic malignancies such as CLL with venetoclax therapy, no such adverse events have been observed in ongoing solid tumor safety and efficacy trials and there were no discontinuations of therapy due to adverse events33. Furthermore, initial reports suggest that venetoclax in conjunction with other therapies, such as tamoxifen, is well-tolerated by patients and demonstrates promising results in tumor treatment33. As BCL2 is an actionable target with an FDA-approved targeted therapy, we believe that the synergy we’ve observed with KAN0441571C and BCL2 inhibitors in SCLC would be of potential clinical benefit. The combination of KAN0441571C and venetoclax is also supported by a recent study showing that there is increased killing efficacy of ROR1-expressing diffuse large B-cell lymphoma (DLBCL) cell lines with the combination therapy compared to either drug alone20. Compared to current standard-of-care immunotherapy plus cisplatin/etoposide chemotherapy, two targeted cancer-specific therapies could have reduced toxicity and provide options for patients relapsing on standard of care therapy. We feel that this combination warrants further investigation to determine its efficacy in SCLC patients.

ROR1 expression has also been associated with cancer stem-like cells (CSCs) as well as those with metastatic potential, and its inhibition has been shown to decrease stem cell markers in CLL1,14,34. It is possible that KAN0441571C and venetoclax demonstrate synergy by targeting separate cell populations in SCLC, with KAN0441571C killing CSCs and venetoclax eliminating the bulk tumor. SCLC has been shown to have significant intratumoral heterogeneity, with a stem-like drug-resistant population supporting a faster proliferating bulk tumor population35. These stem-like cells lack the expression of achaete-scute family BHLH transcription factor 1 (ASCL1), a critical transcription factor in SCLC that is known to drive the expression of BCL2. However, these cells could be ROR1 positive, especially as ROR1 is normally an embryonically expressed protein36,37. Resistance and subsequent repopulation by these CSCs could be the root cause of therapy failure, making the elimination of CSCs a necessity for durable and effective treatment. The combination of ROR1 and BCL2 inhibition could target both of these populations and may represent a promising advance in SCLC therapy options.

Acknowledgements
Tiffany Talabere for support, Rajeswara Arasada for support and critical reading of the manuscript.

Author details
1Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH 43210, USA. 2The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. 3Department of Pathology, The Ohio State University, Columbus, OH 43210, USA. 4Department of Oncology-Pathology, Karolinska Institutet, 17177 Stockholm, Sweden. 5Kancera AB, Banvaktsvägen 22, 17148 Solna, Sweden. 6Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.

Author contributions
Walter Wang: conceptualization, methodology, investigation, visualization, writing—original draft, writing—review & editing. Konstantin Shilo: methodology, investigation, visualization, writing—review & editing. Joseph Amann: methodology, writing—review & editing. Alyssa Shulman: investigation, writing—review & editing. Mohammad Hojat-Farsangi: methodology, resources, writing—review & editing. Håkan Mellstedt: methodology, resources, writing—review & editing. Johan Schultz: resources, writing—review & editing. Carlo Croce: conceptualization, resources, supervision, writing—review & editing. David Carbono: conceptualization, methodology, resources, supervision, writing—review & editing.

Funding
This work was supported by the Schnipke Family Endowment Fund to Support Clinical Trials and Cancer Research; the Robert and Martina Poe Small Cell Carcinoma Fund; and R35CA197706 (CMC).

Ethics statement
This study was approved by the local IRB and The Ohio State University and followed the Declaration of Helsinki Ethical principle for Medical Research Involving Human Subjects. Written informed consent was obtained by all participants prior to inclusion in the study.

Conflict of interest
Dr. Mellstedt reports grants from Kancera AB, personal fees from Kancera AB, outside the submitted work. Dr. Carbone reports personal fees from Abbvie, personal fees from Adaptimmune, personal fees from Agensus, personal fees from Amgen, personal fees from Ariad, personal fees from AstraZeneca, personal fees from Biocept, personal fees from Boehringer Ingelheim, grants and personal fees from Bristol Myers-Squibb, personal fees from Celgene, personal fees from Clovis, personal fees from Daiichi Sankyo Inc., personal fees from EMD Serono, personal fees from Foundation Medicine, personal fees from GenePlus, personal fees from Genentech/Roche, personal fees from Glaxo Smith Kline, personal fees from Gloria Bioscience, personal fees from Gritstone, personal fees from Guardant Health, personal fees from Helixon, personal fees from Humana, personal fees from Incyte, personal fees from Invivata, personal fees from Inovio, personal fees from Janssen, personal fees from Kyowa Kirin, personal fees from Loxo Oncology, personal fees from Merck, personal fees from MSD, personal fees from Nexus Oncology, personal fees from Novartis, personal fees from Palbociclib, personal fees from Pfizer, personal fees from pMIME Oncology, personal fees from Stemcentrx, personal fees from Takeda Oncology, personal fees from Teva, outside the submitted work. The remaining others declare no competing interests.
References

1. Dayer, C. et al. New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases. J. Thorac. Oncol. 9, 5101–5111 (2017).
2. Horn, L. et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N. Engl. J. Med. 379, 2220–2229 (2018).
3. Borcherdinger, N., Kunier, D., Liu, G.-H. & Zhang, W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5, 496–502 (2014).
4. Yamaguchi, T. et al. NKX2-1/TFIIB-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21, 348–361 (2012).
5. Zheng, Y.-Z. et al. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Sci. Rep. 6, 36447 (2016).
6. Rassenti, L. Z. et al. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 114, 10731–10736 (2017).
7. Zhang, S. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl Acad. Sci. USA 111, 17266–17271 (2014).
8. Yamaguchi, T. et al. ROR1 sustains caveloea and survival signalling as a scaffold of cavin-1 and caveloein. Nat. Commun. 7, 10966 (2016).
9. Balakrishnan, A. et al. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin. Cancer Res. 23, 3041–3071 (2017).
10. Higat-Farsangi, M. et al. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia 32, 2291–2295 (2018).
11. Zhang, S. et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc. Natl Acad. Sci. USA 116, 1370–1375 (2017).
12. Daneshmandesh, A. H. et al. A receptor tyrosine kinase: ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and Ibrutinib. PLoS ONE 13, e0198038 (2018).
13. Karachalou, N. et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFRT790M mutation. Transl. Lung Cancer Res 3, 122–130 (2014).
14. Chou, M. Y. et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell 22, 951–959e953 (2018).
15. Pelkasry, Y. & Croce, C. M. Role of miR-15/16 in CLL. Cell Death Differ. 22, 6–11 (2015).
16. Chou, T.-C. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 70, 440 (2010).
17. Tallarida, R. J. Quantitative methods for assessing drug synergism. Genes Cancer 2, 1003–1008 (2011).
18. Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163–3169 (2012).
19. Sircinop-Yao, S. L. et al. Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in NSCLC. J. Thorac. Oncol. 14, 223–236 (2019).
20. Ghaderi, A. et al. ROR1 is expressed in diffuse large B-cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells. Biomedicines 8, 170 (2020).
21. Arasada, R. R. et al. Notch3-dependent β-catenin signaling mediates EGFFR TKI drug persistence in EGFR mutant NSCLC. Nat. Commun. 9, 3196 (2018).
22. Maziur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 21, 1163–1171 (2015).
23. George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).
24. Hart, T., Komori, H. K., LabMere, S., Podshivalova, K. & Salomon, D. R. Finding the active genes in deep RNA-seq gene expression studies. BMC genomics 14, 778–778 (2013).
25. Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944–13949 (2005).
26. Ramirez, R. D. et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64, 9027 (2004).
27. Specht, J. M. et al. Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR-T) cells. J. Clin. Oncol. 36, TPS79–TPS79 (2018).
28. Imai, K. & Takaoa, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714–727 (2006).
29. Adler, S. et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol. Res. Perspect. 3, e0198038–e0198038 (2015).
30. Li, Q. et al. Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials. Front. Pharmacol. 10, 697–697 (2019).
31. Roberts, A. W. et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134, 111–122 (2019).
32. Lochmann, T. L. et al. Venetoclax is effective in small cell lung cancers with high BCL-2 expression. Clin. Cancer Res 24, 360–369 (2018).
33. Lok, S. W. et al. A phase I dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2–positive metastatic breast cancer. Cancer Discov. 9, 354 (2019).
34. Gonzalez, V. D. et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 22, 1875–1888 (2018).
35. Lim, J. S. et al. Intratumoral heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545, 360–364 (2017).
36. Augusty, A. et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc. Natl Acad. Sci. USA 111, 14786–14793 (2014).
37. Rudin, C. M. et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 289–297 (2019).